Over half of individuals taking GLP-1 medications report a decrease in restaurant spending. These drugs, including Wegovy, Mounjaro, and Zepbound, suppress appetite, leading to reduced calorie intake. Morgan Stanley estimates a surge in the global market for GLP-1 drugs, reaching $105 billion by 2030. In the US alone, adoption is projected to reach 31.5 million individuals by 2035. Food industry executives have raised concerns about the potential impact on their businesses. A recent survey reveals that 63% of GLP-1 users spend less on dining out, 61% reduce takeout and delivery expenses, and 31% report lower grocery bills. Morgan Stanley analysts view this shift as manageable but present a challenge for fast-food chains. Healthier fast-casual restaurants like Cava, Chipotle, and Sweetgreen are expected to thrive, while traditional fast-food outlets like Jack in the Box, Wendy’s, and Wingstop may face increased competition.
GLP-1 Drugs Impact Eating Habits and Restaurant Industry
